Extract
Medical guidelines on diagnosis and management of relevant diseases aim to make recommendations for clinical practice while standardising patient care. However, evidence-based guideline development is laborious and challenging, the recommendations require nuanced wording, and the optimal approach remains controversial.
Abstract
Evidence-based guideline development is challenging. Implementation can be suboptimal. A Delphi survey among clinical experts evaluated possibilities to improve clinical utility and implementation of IPF and other ILD guidelines. http://bit.ly/3avcOug
Footnotes
The Erice participants: Carlo Albera (Italy), Goksel Altinisik (Turkey), Kjetil Ask (Canada), Elisabetta Balestro (Italy), Elena Bargagli (Italy), Elisabeth Bendstrup (Denmark), Marialuisa Bocchino (Italy), Francesco Bonella (Germany), Martina Bonifazi (Italy), Giulia Cacopardo (Italy), Maria Rosaria Calvello (Italy), Diego Miguel Castillo Villegas (Spain), Ulrich Costabel (Germany), Vincent Cottin (France), Bruno Crestani (France), Manuela Funke-Chambour (Switzerland), Jack Gauldie (Canada), Peter George (UK), Jan C. Grutters (the Netherlands), Sergio Harari (Italy), Gisli Jenkins (UK), Keri Johannson (Canada), Mark Glynne Jones (UK), Nicolas Carlos Kahn (Germany), Meena Kalluri (Canada), Michael Keane (Ireland), Maria Kokosi (UK), Michael Kreuter (Germany), Donato Lacedonia (Italy), Brett James Ley (USA), Marlies Sandra Lourens Wijsenbeek (the Netherlands), Fabrizio Luppi (Italy), Toby Michael Maher (UK), Georgios Margaritopoulos (UK), Fernando Martinez (USA), Jellerindert Miedema (the Netherlands), Nesrin Mogulkoc Bishop (Turkey), Maria Molina Molina (Spain), Philip Molyneaux (UK), Julie Morisset (Canada), Stefano Palmucci (Italy), Mauro Pavone (Italy), Ganesh Raghu (USA), Elisabetta Renzoni (UK), Luca Richeldi (Italy), Alfredo Sebastiani (Italy), Jacopo Simonetti (Italy), Paolo Spagnolo (Italy), Giulia Maria Stella (Italy), Martina Sterclova (Czech Republic), Irina Strambu (Romania), Sara Tomassetti (Italy), Nazia Chaudhuri Toner (UK), Sebastiano Emanuele Torrisi (Italy), Elisavet Tsitoura (Greece), Haluksaban Turktas (Turkey), Argyrios Tzouvelekis (Greece), Claudia Valenzuela (Spain), Ada Vancheri (Italy), Carlo Vancheri (Italy), Francesco Varone (Italy), Patrizio Vitulo (Italy), Athol Wells (UK) and Wim Wuyts (Belgium).
Conflict of interest: M. Funke-Chambour reports grants from Roche, grants and personal fees for advisory board work from Boehringer Ingelheim, outside the submitted work.
Conflict of interest: C. Albera reports personal fees for advisory board work, consultancy and steering committee work from Roche, MSD and Bayer, personal fees for advisory board work and consultancy from Boheringer Ingelheim, Fibrogen and GSK, grants from Roche and Boheringer Ingelheim, during the conduct of the study.
Conflict of interest: E. Bendstrup reports grants, personal fees and non-financial support from Boehringer Ingelheim and Hoffmann la Roche, outside the submitted work.
Conflict of interest: U. Costabel reports personal fees for consultancy and lectures, and non-financial support from Boehringer and Roche, personal fees for consultancy from Fibrogen, Pliant Therapeutics and Bristol-Myers Squibb, personal fees for lectures from AstraZeneca and Novartis, outside the submitted work.
Conflict of interest: J.C. Grutters has nothing to disclose.
Conflict of interest: S. Harari reports personal fees for lectures and advisory board work from Roche, grants and personal fees for lectures and advisory board work from Actelion and Boehringer Ingelheim, outside the submitted work.
Conflict of interest: K.A. Johannson reports personal fees, non-financial support and other (advisory board work) from Boehringer Ingelheim, personal fees from Hoffman-La Roche Ltd, Blade Therapeutics and Theravance, grants from The Chest Foundation, University of Calgary Cumming School of Medicine, UCB Biopharma SPRL and Pulmonary Fibrosis Society of Calgary, personal fees and non-financial support from Three Lakes Foundation, outside the submitted work.
Conflict of interest: M. Kreuter reports grants and personal fees from Boehringer Ingelheim and Roche, personal fees from Galapagos, outside the submitted work.
Conflict of interest: I. Strambu reports personal fees for advisory board work and lectures from Boehringer Ingelheim, personal fees for lectures from Roche Pharma, AstraZeneca and Novartis, personal fees for investigation work from Galapagos, outside the submitted work.
Conflict of interest: C. Vancheri reports grants and personal fees from Roche and Boehringer Ingelheim, outside the submitted work.
Conflict of interest: F. Varone reports personal fees from Boehringer Ingelheim and Roche, outside the submitted work.
Conflict of interest: P. Vitulo has nothing to disclose.
Conflict of interest: W.A. Wuyts reports grants from Roche and Boehringer Ingelheim, outside the submitted work (paid to institution).
Conflict of interest: F. Martinez reports personal fees for advisory board work, non-financial support for travel and other from AstraZeneca, other (steering committee work and publication) from Afferent/Merck, personal fees for advisory board work, data monitoring committee work, steering committee work and lectures, non-financial support for travel and other (publication) from Boehringer Ingelheim, other (teleconference without compensation) from Bristol Myers Squibb and twoXR, other (travel support) from Chiesi, personal fees for lectures and non-financial support for travel from Canadian Respiratory Society, CME Outfitters, Inova Fairfax, MDMagazine, NYP Methodist Hospital Brooklyn, Miller Communications, National Association for Continuing Education, Novartis, Peer View, Rare Diseases Healthcare Communications and WebMD/MedScape, personal fees for advisory board work and non-financial support for travel from CSL Behring, Sanofi/Regeneron, University of Birmingham Alabama, Sunovion and Teva, personal fees for lectures from Dartmouth University, France Foundation, New York University, Rockpointe Communications and Vindico, personal fees for advisory board work from Gala, Pearl and Verona, personal fees for data monitoring committee and advisory board work, and non-financial support for travel from Genentech, grants, personal fees for advisory board, data monitoring committee and steering committee work, and non-financial support for travel from GlaxoSmithKline, other (steering committee without compensation) from Nitto, personal fees for steering committee work and non-financial support for travel from Patara/Respivant, personal fees for educational activities from Physicians Education Resource and UpToDate, personal fees for steering committee work from ProMedior, other (data monitoring and steering committee without compensation) from Biogen, non-financial support (steering committee) from Veracyte, non-financial support for travel and in-kind study support from Zambon, non-financial support (consultancy and in-kind study support) from ProTerrix Bio, personal fees for consultancy from IQVIA, Raziel and Abvie, outside the submitted work.
Conflict of interest: G. Raghu reports personal fees and other (consultancy) from Boerhinger Ingelheim, Roche, Respivant and Veracyte, other (consultancy and data monitoring committee work) from Avalyn, other (consultancy) from BMS, Biogen, Blade Therapeutics, Bellerophan, Fibrogen, Gilead, Genentech, Nitto and Promedior, and grants from NIH, outside the submitted work.
- Received July 16, 2020.
- Accepted December 9, 2020.
- Copyright ©ERS 2021